Core Insights - Sila Realty Trust, Inc. reported its operating results for the fourth quarter and year ended December 31, 2025, highlighting its strategic focus on the healthcare sector [1][4][20] Financial Performance - For Q4 2025, net income was $5.0 million, or $0.09 per diluted share, down from $11.1 million, or $0.20 per diluted share in Q4 2024 [7][8] - For the year ended December 31, 2025, net income totaled $33.1 million, or $0.60 per diluted share, compared to $42.7 million, or $0.75 per diluted share in 2024 [8] - Cash net operating income (Cash NOI) for Q4 2025 was $44.0 million, an increase from $41.0 million in Q4 2024, primarily due to acquisitions and same-store Cash NOI growth of 0.7% [9] - For the year, Cash NOI was $169.9 million, up from $168.6 million in 2024, with same-store Cash NOI growth of 0.9% [10] Acquisition and Investment Activity - In 2025, the company acquired six healthcare properties for approximately $149 million, totaling about 241,000 rentable square feet [4][7] - The company also fully funded two mezzanine loans for the development of healthcare facilities in Virginia, totaling $17.5 million [7] Portfolio Overview - As of December 31, 2025, Sila's portfolio consisted of 140 properties with approximately 5.3 million rentable square feet and a weighted average remaining lease term of 10 years [13][20] - The percentage of rentable square feet leased was 98.7%, a slight decrease from the previous quarter [14] Balance Sheet and Capital Position - The company reported a liquidity position of approximately $481.3 million, including $32.3 million in cash and $449.0 million available under unsecured credit facilities [15] - Total principal debt outstanding was $676.0 million, with a weighted average interest rate of 4.7% [16] Distributions - The company declared a quarterly cash dividend of $0.40 per share, representing an annualized amount of $1.60 per share [18]

Financial Data and Key Metrics Changes - GAAP net income for the year ended 2024 was $42.7 million or $0.75 per diluted share, compared to $24 million or $0.42 per diluted share for the year ended 2023, indicating significant growth [22] - Cash NOI for the fourth quarter was $41 million, a decrease of 4.3% from $42.8 million in the same period in 2023 [22][23] - AFFO for the fourth quarter was $30.2 million or $0.54 per diluted share, compared to $32.7 million or $0.57 per diluted share during the same period in 2023 [24] Business Line Data and Key Metrics Changes - The company executed renewal leases and lease modifications for over 1.1 million rentable square feet, representing approximately 20% of the total real estate portfolio [15] - The weighted average lease rate increased by 50 basis points to 96% compared to 95.5% at the end of the third quarter [17] - The overall portfolio EBITDARM coverage ratio improved to 5.3 times, with only 1.8% of ABR coming from reporting obligors with EBITDARM coverage ratios below one time [10][18] Market Data and Key Metrics Changes - The company increased exposure to investment grade and rated tenants to 66.9% since the fourth quarter of 2023 [11] - The company noted a lack of new healthcare real estate development, creating a stickier leasing environment [7] - The company is particularly focused on opportunities within the Sunbelt region, also referred to as the "Smile States" [20] Company Strategy and Development Direction - The company aims to enhance the diversity, quality, and size of its healthcare real estate portfolio through strategic acquisitions and capital allocation [7][9] - The company plans to continue executing on its growth strategy in 2025, with a target to grow enterprise value by approximately 7.5% to 15% per annum [33][35] - The company is focused on long-term net lease investments in strategic locations with reliable tenancy sponsorship [35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the improving credit metrics of tenants and the overall health of the healthcare industry [44] - The company anticipates attractive opportunities in the transaction market, despite a higher interest rate environment [20][21] - Management highlighted the importance of maintaining a strong and low to moderately leveraged balance sheet for future growth [27] Other Important Information - The company successfully resolved all exposure related to Genesis Care by re-leasing or selling all 17 assets owned [12] - The company announced a change in the frequency of distributions to stockholders from monthly to quarterly, effective in 2025 [28] - The company has seen a material change in its shareholder base, becoming more institutionally diversified [13] Q&A Session Summary Question: What is the 2025 guidance? - The company indicated a target to grow the enterprise roughly between 7.5% and 15% per annum, with a focus on disciplined growth and accretive assets [33][35] Question: What is the expected mix between loans and acquisitions in 2025? - The majority of transaction volume is expected to be acquisition fee ownership, with some opportunities in loans to fill gaps in development budgets [36][39] Question: Are there any known credit issues or tenant move-outs? - The company reported only one small tenant left, maintaining a high renewal rate and improving credit metrics across the portfolio [42][44] Question: What drove the timing of the Post Acute Medical lease extension? - The extension was driven by a proactive approach and a strong relationship with the tenant, providing them with more certainty as they grow their business [51][52] Question: What is the outlook for the Stoughton facility? - The company is actively marketing the Stoughton property for sale or lease, with interest in both residential and healthcare uses [60][61] Question: Where are the best acquisition opportunities currently? - The company sees attractive opportunities in inpatient rehab and outpatient medical facilities, as well as potential in micro hospitals and urgent care facilities [62]